AGN-242428 + AGN-231868 + Lifitegrast 5% Ophthalmic Solution
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dry Eye Disease
Conditions
Dry Eye Disease, Dry Eye Syndrome
Trial Timeline
Mar 4, 2020 → Mar 18, 2022
NCT ID
NCT04030962About AGN-242428 + AGN-231868 + Lifitegrast 5% Ophthalmic Solution
AGN-242428 + AGN-231868 + Lifitegrast 5% Ophthalmic Solution is a phase 1/2 stage product being developed by AbbVie for Dry Eye Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04030962. Target conditions include Dry Eye Disease, Dry Eye Syndrome.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04030962 | Phase 1/2 | Completed |
Competing Products
20 competing products in Dry Eye Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| UB-312 + Placebo | Vaxxinity | Phase 1 | 25 |
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 2 | 44 |
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 40 |
| exidavnemab + Placebo Comparator | BioArctic AB | Phase 2 | 49 |
| Abiprubart + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| atomoxetine + Matching Placebo | Eli Lilly | Phase 2 | 52 |
| Rosuvastatin 40mg + Placebo | HeartFlow | Pre-clinical | 18 |
| Evolocumab | HeartFlow | Approved | 80 |
| High intensity lipid lowering | HeartFlow | Pre-clinical | 18 |
| Apixaban 5 MG + Apixaban 2.5 MG + Warfarin | Artivion | Phase 3 | 72 |
| Lanifibranor | Inventiva | Phase 2 | 47 |
| LY450139 + Placebo | Eli Lilly | Phase 3 | 77 |
| Dulaglutide + Placebo | Eli Lilly | Phase 3 | 77 |
| raloxifene + placebo | Eli Lilly | Phase 3 | 77 |
| VTX958 + VTX958 + VTX958 Placebo | Ventyx Biosciences | Phase 2 | 47 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 52 |
| Zagotenemab + Placebo | Eli Lilly | Phase 2 | 52 |
| Donanemab + Placebo + LY3202626 | Eli Lilly | Phase 2 | 52 |
| Donanemab + Placebo | Eli Lilly | Phase 3 | 77 |